Ineffectiveness of Intermittent Hemodialysis in a Critically Ill COVID-19 Patient: A Case of Persistent Heparin-Induced Hyperkalemia

• Published in: Case Reports in Nephrology Vol. 2022; pp. 8613656 - 4
• Main Authors: Nlandu, Yannick M., Engole, Yannick M., Mboliassa, Marie-France I., Sakaji, Théodore-Junior M., Kobo, Patrick U., Boloko, Patrick M., Mafuta, Pally K., Tsangu, Joseph P., Van Echkout, Karel, Kanku, Jean-Pierre M., Kalifa, Golan, Ahmed, Rodolphe, Bukabau, Justine B.
• Format: Journal Article
• Language: English
• Published: United States Hindawi 2022; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Aldosterone; Antibiotics; Anticoagulants; Antigens; Blood; Care and treatment; Case Report; Case reports; Complications and side effects; Coronaviruses; COVID-19; Dialysate; Dialyzers; Hemodialysis; Hemoglobin; Heparin; Hydrochlorothiazide; Hyperkalemia; Imipenem; Intubation; Kidneys; Laboratories; Physiological aspects; Potassium; Rhabdomyolysis; Rivaroxaban; Severe acute respiratory syndrome coronavirus 2; Ventilators; Congo (Kinshasa)
• ISSN: 2090-6641; 2090-665X
• DOI: 10.1155/2022/8613656

Heparin is widely used in the intensive care unit despite the risk of bleeding it can cause. Although it is rarely reported, hyperkalemia is one of the side effects associated with heparin therapy (unfractionated or fractionated heparin). It would be secondary to hypoaldosteronism by blocking the biosynthesis of aldosterone in the adrenal gland and often appears in context of prolonged heparin therapy or inappropriate renin production in elderly, diabetic, and kidney insufficiency patients. We report a case of persistent hyperkalemia in a diabetic COVID-19 patient treated with curative heparin in the context of severe COVID-19.